Measles virus causes immunogenic cell death in human melanoma

166Citations
Citations of this article
134Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Oncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma. This study demonstrates the efficacy of MV against human melanoma. It is increasingly recognised that an essential component of therapy with OV is the recruitment of host antitumour immune responses, both innate and adaptive. MV-mediated melanoma cell death is an inflammatory process, causing the release of inflammatory cytokines including type-1 interferons and the potent danger signal HMGB1. Here, using human in vitro models, we demonstrate that MV enhances innate antitumour activity, and that MV-mediated melanoma cell death is capable of stimulating a melanoma-specific adaptive immune response. © 2013 Macmillan Publishers Limited All rights reserved.

Cite

CITATION STYLE

APA

Donnelly, O. G., Errington-Mais, F., Steele, L., Hadac, E., Jennings, V., Scott, K., … Melcher, A. A. (2013). Measles virus causes immunogenic cell death in human melanoma. Gene Therapy, 20(1), 7–15. https://doi.org/10.1038/gt.2011.205

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free